Clinical Trial

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 10, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: a two-week screening phase/run-in and a six-week double-masked treatment phase.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06225973
Lead Sponsor Telios Pharma, Inc.
Conditions Dry Eye Disease
Enrollment 880 participants
Start Date 2024-02-06
Primary Completion 2024-12 (estimated)
Study Completion 2024-12 (estimated)
Updated on ClinicalTrials.gov 2024-07-10